[Correspondence] Questions in the design of ANSWER
Trials including participants with advanced liver disease are challenging. In the open-label ANSWER trial, Paolo Caraceni and colleagues (May 31, p 2417)1 aimed to assess the effect of long-term albumin administration in decompensated cirrhosis on overall survival. The authors conclude that albumin administration is associated with improved overall survival. However, it is unclear whether this finding is robust.